Surrozen, Inc. Common (SRZN) Stock Price

SRZNStock

$23.44+72.35%52W

Market Cap$275.50M

P/E—

PEG Ratio—

Div yield—

Beta0.55

SRZN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-36.31%

Price vs S&P 500 (4W)43.13%

VGM Score51.74

Book Value / Share (Quarterly)$5.50

P/TBV (Annual)0.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.72%

Cash Flow / Share (Quarterly)$-2.98

Price vs S&P 500 (YTD)-8.21%

Net Profit Margin (TTM)-2885.33%

EPS (TTM)$-35.79

10-Day Avg Trading Volume0.65M

EPS Excl Extra (TTM)$-35.79

EPS (Annual)$-32.37

ROI (Annual)-113.46%

Cash / Share (Quarterly)$8.68

Revenue Growth QoQ (YoY)408.65%

ROA (Last FY)-245.15%

Revenue Growth TTM (YoY)-8.79%

EBITD / Share (TTM)$-4.38

ROE (5Y Avg)-72.54%

Operating Margin (TTM)-385.28%

Cash Flow / Share (Annual)$-3.11

P/B Ratio5.85x

P/B Ratio (Quarterly)1.63x

Net Income / Employee (Annual)$-5,500,600

EV / Revenue (TTM)15.07x

Net Interest Coverage (TTM)-2.40x

ROA (TTM)-309.62%

EPS Growth QoQ (YoY)-7.55%

EPS Incl Extra (Annual)$-32.37

Current Ratio (Annual)9.22x

Quick Ratio (Quarterly)11.88x

3-Month Avg Trading Volume0.43M

52-Week Price Return72.35%

Revenue / Employee (TTM)$261,600

Tangible BV / Share (Quarterly)$1.80

P/S Ratio (Annual)79.24x

Asset Turnover (Annual)0.04x

52-Week High$37.83

EPS Excl Extra (Annual)$-32.37

CapEx CAGR (5Y)-31.84%

26-Week Price Return-26.41%

Quick Ratio (Annual)9.01x

13-Week Price Return6.74%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.14x

Enterprise Value$173.46M

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$79,000

Pretax Margin (Annual)-6960.77%

Cash / Share (Annual)$9.13

3-Month Return Std Dev231.35%

Net Income / Employee (TTM)$-7,548,400

ROE (Last FY)-113.46%

EPS Basic Excl Extra (Annual)$-32.37

Receivables Turnover (TTM)3.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-35.79

Receivables Turnover (Annual)2.53x

ROI (TTM)58.23%

P/S Ratio (TTM)23.93x

Revenue / Share (Annual)$0.47

Tangible BV / Share (Annual)$2.53

Price vs S&P 500 (52W)56.82%

Year-to-Date Return3.72%

5-Day Price Return-5.33%

EPS Normalized (Annual)$-32.37

ROA (5Y Avg)-109.96%

Net Profit Margin (Annual)-6960.77%

Month-to-Date Return-27.16%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-5.56

Operating Margin (Annual)-1210.58%

ROI (5Y Avg)-72.54%

EPS Basic Excl Extra (TTM)$-35.79

P/TBV (Quarterly)0.20x

P/B Ratio (Annual)0.51x

Pretax Margin (TTM)-2885.33%

Book Value / Share (Annual)$18.39

Price vs S&P 500 (13W)4.05%

Beta0.55x

Revenue / Share (TTM)$0.99

ROE (TTM)58.23%

52-Week Low$11.39

vGradeD

gGradeC

mGradeB

vgmGradeC

SRZN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.26	-$2.10	-66.79%(-$0.84)
Q1 2026	May 6, 2026	-$0.72	-$4.63	-542.50%(-$3.91)
Q4 2025	Mar 23, 2026	-$1.24	-$9.62	-678.79%(-$8.38)
Q3 2025	Nov 7, 2025	-$1.17	-$3.60	-208.09%(-$2.43)
Q2 2025	Aug 8, 2025	-$1.23	-$1.14	+7.55%(+$0.09)

SRZN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.18

4.25

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SRZNSurrozen, Inc. Common	D	C	B	23.9x	-8.8%	—	—	$23.44
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Surrozen, Inc. Common

Surrozen is a clinical-stage biotechnology company developing selective Wnt pathway modulators to promote tissue repair and regeneration across multiple organs. The company's pipeline includes three product candidates designed to address significant unmet medical needs in regenerative medicine. By targeting the Wnt signaling pathway, Surrozen aims to unlock the body's natural tissue repair mechanisms.

SRZN Insider Transactions

SellJul 22, 2026
TCG CROSSOVER GP II, L.L.C
Beneficial Owner of more than 10% of a Class of Security
Shares: 325,000Value: $6.91M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for July 2026

Companies in Related Industries

GEVOGevo, Inc.Industrial Chemicals
USNAUSANA Health Sciences IncPharmaceutical Preparations
BNTCBenitec Biopharma Inc. Common StockPharmaceuticals
FULCFulcrum Therapeutics, Inc. Common StockPharmaceuticals
CYPHCypherpunk Technologies Inc. Common StockPharmaceuticals
ALTOAlto Ingredients, Inc. Common StockIndustrial Chemicals
CTNMContineum Therapeutics, Inc. Class A Common StockPharmaceuticals
PRLDPrelude Therapeutics IncorporatedPharmaceuticals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$11.39

High$37.83